J.P. Morgan analyst Anupam Rama maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) yesterday and set a price target of $40.00. The company’s shares closed yesterday at
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) yesterday and set a price target of $40.00. The company’s shares closed yesterday at
Kiniksa Pharmaceuticals ($KNSA) recently announced its Q3 results, which exceeded expectations with a 67% revenue upsurge to $112.2 million, outperforming the anticipated $111.5 million. This growth was spearheaded by the heightened demand
Kiniksa Pharmaceuticals Ltd. Class A (KNSA) has disclosed a new risk, in the Capital Markets category. Kiniksa Pharmaceuticals Ltd. Class A faces significant risks associated with exchange rate fluctuations, which
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Kiniksa Pharmaceuticals (KNSA – Research Report) and Insmed (INSM – Research Report) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
Evercore ISI analyst Cory Kasimov maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $115.00. The company’s shares closed last Tuesday at $69.91, close to its 52-week low of $67.75.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $102.39, implying a 46.7% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $86.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Kiniksa Pharmaceuticals (KNSA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Kiniksa Pharmaceuticals today and set a price target of $35.00. The company’s shares closed last Tuesday at $23.27.
According to TipRanks.com, Bayko is a 4-star analyst with an average return of
Currently, the analyst consensus on Kiniksa Pharmaceuticals is a Strong Buy with an average price target of $37.25, implying a 74.7% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $35.00 price target.
Insmed (INSM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed today. The company’s shares closed last Tuesday at $70.95, close to its 52-week high of $80.53.
According to TipRanks.com, Suvannavejh has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $87.11, which is a 22.8% upside from current levels. In a report issued on October 28, Bank of America Securities also maintained a Buy rating on the stock.
Read More on BMRN:
Analyst Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) and keeping the price target at $35.00. Eva Fortea Verdejo’s rating is